Second Cancer Risk Mainly Confined To Same Type Recurrence
Worldwide, approximately 15% of cancer survivors are diagnosed with a second primary cancer. A study published in the Canadian Medical Association Journal (CMAJ) reveals that those who have survived cancer are at more than double the risk of a second primary cancer of the same type, but the risk of developing a second cancer of a different type is only marginally higher. To establish whether the risk of secondary cancer is associated to the first diagnosed cancer, Danish researchers evaluated data for the entire Danish population (7, 493, 705 people) from 1980 to 2007.
Everolimus Prolongs Progression-Free Survival For Patients With Neuroendocrine Tumors
Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, according to researchers at The University of Texas MD Anderson Cancer Center. Results of the international, randomized, placebo-controlled Phase III study were published in the journal Lancet. The treatment combination of everolimus and octreotide long-acting repeatable (LAR), a somatostatin analogue that has shown antitumor activity, led to a clinically meaningful five-month delay in tumor growth, compared to octreotide alone.
Potential Link Between Cancer And A Common Chemical In Consumer Products
A study led by a group of Nanyang Technological University (NTU) researchers has found that a chemical commonly used in consumer products can potentially cause cancer. The chemical, Zinc Oxide, is used to absorb harmful ultra violet light. But when it is turned into nano-sized particles, they are able to enter human cells and may damage the user's DNA. This in turn activates a protein called p53, whose duty is to prevent damaged cells from multiplying and becoming cancerous. However, cells that lack p53 or do not produce enough functional p53 may instead develop into cancerous cells when they come into contact with Zinc Oxide nanoparticles.